Cytokinetics, Incorporated (CYTK) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $63.54: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Below-average business quality; Negative price momentum.
Cytokinetics is a specialty biopharmaceutical company focused on muscle biology, with its first commercial product MYQORZO (aficamten) FDA-approved in December 2025 for obstructive hypertrophic cardiomyopathy. Revenue will come from MYQORZO sales (launched January 2026);... Read more
Sell if holding. Engine safety override at $63.54: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Below-average business quality; Negative price momentum. Chart setup: RSI 45 mid-range, Bollinger mid-band. Score 4.8/10, moderate confidence.
Passes 4/6 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and earnings proximity 5d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductMYQORZO10-K Item 1A: 'We currently rely on single source CMOs for the manufacture of any or all of MYQORZO as a finished drug product and the active pharmaceutical ingredient and registered starting materials used in the production of MYQORZO'
- HIGHSuppliersingle source CMOs10-K Item 1A: 'We currently rely on single source CMOs for the manufacture of any or all of MYQORZO as a finished drug product and the active pharmaceutical ingredient and registered starting materials used in the production of MYQORZO'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $63.54: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Below-average business quality; Negative price momentum. Chart setup: RSI 45 mid-range, Bollinger mid-band. Prior stop was $59.08. Score 4.8/10, moderate confidence.
Take-profit target: $83.65 (+31.7% upside). Prior stop was $59.08. Stop-loss: $59.08.
Concentration risk — Product: MYQORZO; Concentration risk — Supplier: single source CMOs; Quality below floor (2.6 < 4.0).
Cytokinetics, Incorporated trades at a P/E of N/A (forward -12.0). TrendMatrix value score: 9.0/10. Verdict: Sell.
26 analysts cover CYTK with a consensus score of 4.0/5. Average price target: $93.
What does Cytokinetics, Incorporated do?Cytokinetics is a specialty biopharmaceutical company focused on muscle biology, with its first commercial product...
Cytokinetics is a specialty biopharmaceutical company focused on muscle biology, with its first commercial product MYQORZO (aficamten) FDA-approved in December 2025 for obstructive hypertrophic cardiomyopathy. Revenue will come from MYQORZO sales (launched January 2026); pipeline includes omecamtiv mecarbil for heart failure and earlier-stage candidates.